Global Competitor Insights for Orthopedic Biomaterials

Table of Contents

TABLE OF CONTENTS

LIST OF EXHIBITS

METHODOLOGY

1.0 ALLO SOURCE

• 1.1 Company Overview
• 1.2 Products Offered
• 1.3 Recent Events⁄Strategy
• 1.4 Financial Overview
• 1.5 S.W.O.T. Analysis
  • 1.5.1 Strengths
  • 1.5.2 Weaknesses
  • 1.5.3 Opportunities
  • 1.5.4 Threats

2.0 BIOMET

• 2.1 Company Overview
• 2.2 Products Offered
  • 2.2.1 Bone Graft Substitutes
  • 2.2.2 Hyaluronic Acid Viscosupplementation
  • 2.2.3 Platelet Concentration Systems
  • 2.2.4 Growth Factors
  • 2.2.5 Machined Bone Products
• 2.3 Recent Events⁄Strategy
• 2.4 Financial Overview
• 2.5 S.W.O.T. Analysis
  • 2.5.1 Strengths
  • 2.5.2 Weaknesses
  • 2.5.3 Opportunities
  • 2.5.4 Threats

3.0 BIOMIMETIC PHARMACEUTICALS

• 3.1 Company Overview
• 3.2 Products Offered
• 3.3 Recent Events⁄Strategy
• 3.4 S.W.O.T. Analysis
  • 3.4.1 Strengths
  • 3.4.2 Weaknesses
  • 3.4.3 Opportunities
  • 3.4.4 Threats

4.0 CERAPEDICS

• 4.1 Company Overview
• 4.2 Products Offered
• 4.3 Recent Events⁄Strategy
• 4.4 S.W.O.T. Analysis
  • 4.4.1 Strengths
  • 4.4.2 Weaknesses
  • 4.4.3 Opportunities
  • 4.4.4 Threats

5.0 DEPUY (A J& J CO. )

• 5.1 Company Overview
• 5.2 Products Offered
  • 5.2.1 Bone Graft Substitutes
  • 5.2.2 Growth Factors
  • 5.2.3 Platelet Concentration Systems
  • 5.2.4 Other
• 5.3 Recent Events⁄Strategy
• 5.4 Financial Overview
• 5.5 S.W.O.T. Analysis
  • 5.5.1 Strengths
  • 5.5.2 Weaknesses
  • 5.5.3 Opportunities
  • 5.5.4 Threats

6.0 FIDIA FARMACEUTICI

• 6.1 Company Overview
• 6.2 Products Offered
  • 6.2.1 Autologous Chondrocyte Implantation
  • 6.2.2 Hyaluronic Acid Viscosupplementation
• 6.3 Financial Overview
• 6.4 S.W.O.T. Analysis
  • 6.4.1 Strengths
  • 6.4.2 Weaknesses
  • 6.4.3 Opportunities
  • 6.4.4 Threats

7.0 GENZYME BIOSURGERY (VERIGEN AG)

• 7.1 Company Overview
• 7.2 Products Offered
  • 7.2.1 Productson the Market
  • 7.2.2 Products in Development
• 7.3 Recent Events⁄Strategy
• 7.4 Financial Overview
• 7.5 S.W.O.T. Analysis
  • 7.5.1 Strengths
  • 7.5.2 Weaknesses
  • 7.5.3 Opportunities
  • 7.5.4 Threats

8.0 ISOTIS ORTHOBIOLOGICS

• 8.1 Company Overview
• 8.2 Products Offered
  • 8.2.1 Bone Graft Substitutes
• 8.3 Recent Events⁄Strategy
• 8.4 Financial Overview
• 8.5 S.W.O.T. Analysis
  • 8.5.1 Strengths
  • 8.5.2 Weaknesses
  • 8.5.3 Opportunities
  • 8.5.4 Threats

9.0 MEDTRONIC SOFAMOR DANEK

• 9.1 Company Overview
• 9.2 Products Offered
  • 9.2.1 Spinal AlloGrafts
  • 9.2.2 Bone Graft Substitutes
  • 9.2.3 Growth Factors
• 9.3 Recent Events⁄Strategy
• 9.4 Financial Overview
• 9.5 S.W.O.T. Analysis
  • 9.5.1 Strengths
  • 9.5.2 Weaknesses
  • 9.5.3 Opportunities
  • 9.5.4 Threats

10.0 MUSCULOSKELETAL TRANSPLANT FOUNDATION

• 10.1 Company Overview
• 10.2 Products Offered
  • 10.2.1 Bone Graft Substitutes
  • 10.2.2 Spinal AlloGrafts
  • 10.2.3 Allofix Cortica l Bone Pinsand Screws
• 10.3 Recent Events⁄Strategy
• 10.4 Financial Overview
• 10.5 S.W.O.T. Analysis
  • 10.5.1 Strengths
  • 10.5.2 Weaknesses
  • 10.5.3 Opportunities
  • 10.5.4 Threats

11.0 ORTHOLOGIC

• 11.1 Company Profile
• 11.2 Products Offered
• 11.2.1 Chrysalin
• 11.3 Recent Events⁄Strategy
• 11.4 S.W.O.T. Analysis
  • 11.4.1 Strengths
  • 11.4.2 Weaknesses
  • 11.4.3 Opportunities
  • 11.4.4 Threats

12.0 ORTHOVITA

• 12.1 Company Profile
• 12.2 Products Offered
• 12.2.1 Bone Graft Substitutes
• 12.3 Recent Events⁄Strategy
• 12.4 Financial Overview
• 12.5 S.W.O.T. Analysis
  • 12.5.1 Strengths
  • 12.5.2 Weaknesses
  • 12.5.3 Opportunities
  • 12.5.4 Threats

13.0 OSTEOTECH, INC

• 13.1 Company Overview
• 13.2 Products Offered
  • 13.2.1 Spinal AlloGrafts
  • 13.2.2 Bone Graft Substitutes
• 13.3 Recent Events⁄Strategy
• 13.4 Financial Overview
• 13.5 S.W.O.T. Analysis
  • 13.5.1 Strengths
  • 13.5.2 Weaknesses
  • 13.5.3 Opportunities
  • 13.5.4 Threats

14.0 Q-MED

• 14.1 Company Overview
• 14.2 Products Offered
  • 14.2.1 Hyaluronic Acid Viscosupplementation
• 14.3 Recent Events⁄Strategy
• 14.4 Financial Overview
• 14.5 S.W.O.T. Analysis
  • 14.5.1 Strengths
  • 14.5.2 Weaknesses
  • 14.5.3 Opportunities
  • 14.5.4 Threats

15.0 REGENERATION TECHNOLOGIES

• 15.1 Company Overview
• 15.2 Products Offered
  • 15.2.1 Bone Graft Substitutes
  • 15.2.2 Maxillofacial Fixation and BGS
  • 15.2.3 Spinal AlloGrafts
  • 15.2.4 Sports Medicine AlloGrafts
• 15.3 Recent Events⁄Strategy
• 15.4 Financial Overview
• 15.5 S.W.O.T. Analysis
  • 15.5.1 Strengths
  • 15.5.2 Weaknesses
  • 15.5.3 Opportunities
  • 15.5.4 Threats

16.0 SMITH & NEPHEW

• 16.1 Company Overview
• 16.2 Products Offered
  • 16.2.1 Hyaluronic Acid Viscosupplementation
  • 16.2.2 Cartilage Repair Products
  • 16.2.3 Bone Graft Substitutes
• 16.3 Recent Events⁄Strategy
• 16.4 Financial Overview
• 16.5 S.W.O.T. Analysis
  • 16.5.1 Strengths
  • 16.5.2 Weaknesses
  • 16.5.3 Opportunities
  • 16.5.4 Threats

17.0 STRYKER CORPORATION

• 17.1 Company Overview
• 17.2 Products Offered
  • 17.2.1 Growth Factors
  • 17.2.2 Bone Graft Substitutes
• 17.3 Recent Events⁄Strategy
• 17.4 Financial Overview
• 17.5 S.W.O.T. Analysis
  • 17.5.1 Strengths
  • 17.5.2 Weaknesses
  • 17.5.3 Opportunities
  • 17.5.4 Threats

18.0 SYNTHES

• 18.1 Company Overview
• 18.2 Products Offered
  • 18.2.1 Spinal AlloGrafts
  • 18.2.2 Bone Graft Substitutes
• 18.3 Recent Events⁄Strategy
• 18.4 Financial Overview
• 18.5 S.W.O.T. Analysis
  • 18.5.1 Strengths
  • 18.5.2 Weaknesses
  • 18.5.3 Opportunities
  • 18.5.4 Threats

19.0 TUTOGEN

• 19.1 Company Profile
• 19.2 Products Offered
  • 19.2.1 Spinal AlloGrafts
• 19.3 Recent Events⁄Strategy
• 19.4 Financial Overview
• 19.5 S.W.O.T. Analysis
  • 19.5.1 Strengths
  • 19.5.2 Weaknesses
  • 19.5.3 Opportunities
  • 19.5.4 Threats

20.0 WRIGHT MEDICAL TECHNOLOGIES

• 20.1 Company Overview
• 20.2 Products Offered
  • 20.2.1 DBM Products
  • 20.2.2 Synthetic Bone Graft Substitutes
  • 20.2.3 Products in Developm en t
• 20.3 Recent Events⁄Strategy
• 20.4 Financial Overview
• 20.5 S.W.O.T. Analysis
  • 20.5.1 Strengths
  • 20.5.2 Weaknesses
  • 20.5.3 Opportunities
  • 20.5.4 Threats

21.0 ZIMMER

• 21.1 Company Overview
• 21.2 Products Offered
  • 21.2.1 Bone Graft Substitutes
• 21.3 Recent Events⁄Strategy
• 21.4 Financial Overview
• 21.5 S.W.O.T. Analysis
  • 21.5.1 Strengths
  • 21.5.2 Weaknesses
  • 21.5.3 Opportunities
  • 21.5.4 Threats
• 21.6 S.W.O.T. Analysis
  • 21.6.1 Strengths
  • 21.6.2 Weaknesses
  • 21.6.3 Opportunities
  • 21.6.4 Threats

APPENDIX A: LIST OF ABBREVIATIONS